

**Regd. Office :-**  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



To  
BSE LIMITED  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400 001

20<sup>th</sup> May 2025

Dear Sir/Madam

**Subject:** Audited Standalone & Consolidated Financial Statements & Results for the Quarter and Year ended 31<sup>st</sup> March 2025

**Ref:**      **BSE Scrip ID:** CHEMCRUX                      **BSE Scrip Code:** 540395

We would like to inform that the Board of Directors in its meeting held today i.e., Tuesday, 20<sup>th</sup> May 2025 inter alia, considered and approved the Audited Standalone & Consolidated Financial Statements & Results for the quarter and year ended 31<sup>st</sup> March 2025 as recommended by the Audit Committee. The Board also recommended Final Dividend for F.Y. 2024-25 at the rate of 10% (Re. 1/- per share) on the Equity share of Rs. 10/- each subject to the approval of shareholders in the ensuing Annual General Meeting.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the herewith copy of the Audited Financial Results (Standalone and Consolidated) for the quarter & year ended 31<sup>st</sup> March 2025 along with the Auditor's Report issued by the Statutory Auditors of the Company. Further, declaration as to unmodified opinion of Auditors on the Audited Financial Statements & Results is also attached.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 03.00 P.M. and concluded at 06.25 P.M.

Thanking you

**For CHEMCRUX ENTERPRISES LIMITED**

**Dipika Rajpal**  
**Company Secretary & Compliance Officer**

## CHEMCRIX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

## AUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2025

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	Quarter Ended			Year ended	
		31-03-2025 Audited	31-12-2024 Unaudited	31-03-2024 Audited	31-03-2025 Audited	31-03-2024 Audited
I.	Revenue from operations	1,596.56	1,942.36	1,853.68	7,025.39	7,846.53
II.	Other income	27.74	60.55	34.70	152.96	133.55
III.	<b>Total Income ( I+II)</b>	<b>1,624.30</b>	<b>2,002.91</b>	<b>1,888.39</b>	<b>7,178.35</b>	<b>7,980.07</b>
IV.	<b>Expenses:</b>					
	Cost of materials consumed	733.32	869.45	794.14	3,042.21	2,533.25
	Purchase of Traded Goods	-	-	-	-	-
	Changes in inventories of finished goods, by-products and work in progress	(187.64)	(60.10)	(153.44)	236.26	579.79
	Employee benefits expense	218.59	217.48	201.37	852.68	882.91
	Finance costs	58.29	59.60	13.00	163.84	83.24
	Depreciation and amortization expense	91.46	92.09	55.04	313.06	228.52
	Other expenses	637.47	646.08	748.88	2,460.01	2,529.21
	<b>Total expenses (IV)</b>	<b>1,551.50</b>	<b>1,824.61</b>	<b>1,659.00</b>	<b>6,595.54</b>	<b>6,836.92</b>
V.	<b>Profit Before Tax</b>	<b>72.79</b>	<b>178.30</b>	<b>229.39</b>	<b>582.81</b>	<b>1,143.15</b>
VIII.	<b>Tax expense :</b>					
	Current tax	2.66	27.04	50.19	75.00	285.00
	Deferred tax	22.62	19.59	(12.59)	90.06	11.89
	Income tax relating to earlier years	0.07	(1.17)	(29.45)	(1.11)	1.83
		<b>25.35</b>	<b>45.46</b>	<b>8.15</b>	<b>163.96</b>	<b>298.72</b>
IX.	<b>Profit for the period</b>	<b>47.45</b>	<b>132.84</b>	<b>221.24</b>	<b>418.86</b>	<b>844.43</b>
X.	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to profit or loss					
	- Defined Benefit Plan	18.88	3.47	(20.18)	26.18	(45.09)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.75	0.87	(5.08)	6.59	(11.35)
	(iii) Items that will be reclassified to profit or loss					
	-Fair Value Gain on Investments	39.91	11.85	39.19	126.92	133.65
	(iv) Income tax relating to items that will be reclassified to profit or loss	10.04	2.98	9.86	31.95	33.64
	<b>Total other comprehensive income, net of tax</b>	<b>43.99</b>	<b>11.46</b>	<b>14.22</b>	<b>114.57</b>	<b>66.27</b>
XI.	<b>Total comprehensive income for the period</b>	<b>91.44</b>	<b>144.30</b>	<b>235.47</b>	<b>533.42</b>	<b>910.70</b>
XII.	<b>Earnings per equity share (Nominal value per share Rs. 10/-)</b>					
	- Basic (Rs.)	0.32	0.90	1.49	2.83	5.70
	- Diluted (Rs.)	0.32	0.90	1.49	2.83	5.70




*Handwritten signature*

**Notes to Standalone Financial Results :**

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 2 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 20th May, 2025.
- 3 The above financial results have been audited by the Statutory Auditors as required under Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended.
- 4 During the fourth quarter of the current year, the Company acquired an additional 50% equity interest in Kalichem Private Limited, which was previously a joint venture with 50% ownership. As a result of this acquisition, Kalichem Private Limited has become a wholly-owned subsidiary of the Company effective from 27.02.2025. This transaction does not impact these standalone financial results except for disclosure of the investment in the subsidiary.
- 5 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of Ind AS 108, on Operating Segment, constitute a single operating segment.
- 6 The Board of Directors of the Company at its Board Meeting held on 20th May 2025, recommended a dividend @ 10% (i.e. Rs.1/- per share of FV Rs. 10/- each) as Final Dividend for the year ended on 31st March 2025, subject to the approval of the same by the shareholders in the ensuing annual general meeting.
- 7 The figures of the quarter ended 31st March, 2025 and 31st March, 2024 represent the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial year which were subject to limited review by the Statutory Auditors as required under the Listing Regulations
- 8 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board**  
**Chemcrux Enterprises Limited**

  
Girish Kumar Shah  
Whole Time Director  
DIN : 00469291



Place : Vadodara  
Date : 20th May, 2025

CHEMCRUX ENTERPRISES LIMITED			
CIN : L01110GJ1996PLC029329			
Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007			
STANDALONE BALANCE SHEET AS AT 31ST MARCH, 2025			
(Figures in Rs Lacs)			
	Particulars	As at 31st March, 2025	As at 31st March, 2024
I.	<b>ASSETS</b>		
(1)	<b>Non - Current Assets</b>		
	(a) Property, Plant and Equipment	5,639.86	3,182.84
	(b) Capital Work In Progress	161.08	2,105.78
	(c) Investment Property	67.78	67.78
	(d) Right of Use Assets	44.23	56.57
	(e) Other Intangible Assets	2.84	1.54
	(f) Financial Assets		
	(i) Investments	5.70	5.17
	(ii) Loans	559.00	350.00
	(iii) Others	275.47	234.04
	(g) Other Non - Current Assets	-	-
(2)	<b>Current Assets</b>		
	(a) Inventories	964.89	841.06
	(b) Financial Assets		
	(i) Investments	1,978.15	1,977.41
	(ii) Trade Receivables	1,221.30	1,529.98
	(iii) Cash and Cash Equivalents	101.38	7.09
	(iv) Other Bank Balances	12.88	511.14
	(v) Loans	23.48	23.02
	(vi) Others	6.21	6.18
	(c) Other Current Assets	150.28	87.07
	<b>Total Assets</b>	<b>11,214.51</b>	<b>10,986.68</b>
II.	<b>EQUITY AND LIABILITIES</b>		
(1)	<b>Equity</b>		
	(a) Equity Share Capital	1,480.88	1,480.88
	(b) Other Equity	6,130.30	5,744.97
	<b>Liabilities</b>		
(2)	<b>Non - Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Long Term Borrowings	1,787.74	2,152.68
	(ii) Lease Liabilities	60.70	77.24
	(iii) Other Financial Liabilities	-	-
	(b) Provisions	5.57	17.56
	(c) Deferred Tax Liability (net)	346.46	217.86
(3)	<b>Current Liabilities</b>		
	(a) Financial liabilities		
	(i) Short Term Borrowings	816.02	401.96
	(ii) Lease Liabilities	16.54	13.35
	(iii) Trade Payables		
	a) Total Outstanding Dues of Micro Enterprises and Small Enterprises	26.44	264.41
	b) Total Outstanding Dues of Creditors Others than Micro Enterprises and Small Enterprises	374.66	333.61
	(iv) Other Financial Liabilities	60.42	159.69
	(c) Other Current Liabilities	108.77	106.96
	(b) Provisions	-	-
	(d) Current Tax Liabilities (Net)	-	15.52
	<b>Total Equity and Liabilities</b>	<b>11,214.51</b>	<b>10,986.68</b>

For & on behalf of the Board  
Chemcrux Enterprises Limited

Girish Kumar Shah  
Whole Time Director  
DIN : 00469291

Place : Vadodara  
Date : 20th May, 2025



CHEMCRUX ENTERPRISES LIMITED			
CIN : L01110GJ1996PLC029329			
Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007			
STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2025			
(Figures in Rs Lacs)			
Sr.	Particulars	Year ended 31st March , 2025	Year ended 31st March , 2024
A.	<b>Cash flow from Operating Activities :</b>		
	Net Profit before Tax & Extra Ordinary Items	582.81	1,143.15
	Adjustment for :		
	Depreciation & Write-offs	313.06	228.52
	Loss/(Profit) on Sale of PPE	(5.98)	16.84
	Interest Expense	163.84	83.24
	Interest Income	(74.67)	(39.17)
	Gain on Mutual Funds	(23.81)	(34.38)
	Gratuity Expense	14.20	7.22
	<b>Operating Profit before Working Capital Changes</b>	<b>969.45</b>	<b>1,405.43</b>
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	308.69	(186.06)
	(Increase)/Decrease in Inventories	(123.83)	568.01
	(Increase)/Decrease in Loans & Advances	(0.49)	(12.55)
	(Increase)/Decrease in other current assets	4.71	280.76
	Increase/(Decrease) in Trade Payable	(196.91)	(205.21)
	Increase/(Decrease) in Other Current Liabilities	(112.98)	35.43
	Increase/(Decrease) in Long term provisions	-	17.56
	<b>Cash Generated from Operating Activities</b>	<b>848.64</b>	<b>1,903.36</b>
	Direct Taxes Paid	(141.82)	(269.48)
	<b>Cash Flow before Extra Ordinary Items</b>	<b>706.82</b>	<b>1,633.88</b>
	Prior Period Items ( being cash items )	-	-
	<b>Net Cash Flow from Operating Activities</b>	<b>706.82</b>	<b>1,633.88</b>
B.	<b>Cash Flow from Investing Activities</b>		
	Purchase of PPE	(825.35)	(2,428.51)
	Net Proceeds from Sale of PPE	17.00	110.00
	Dividend Received	-	-
	Investments (Net)	149.48	(239.76)
	Loan Given to Related Parties	(209.00)	(70.00)
	Interest Received	74.67	39.17
	<b>Net Cash used in Investment Activities</b>	<b>(793.21)</b>	<b>(2,589.10)</b>
C.	<b>Cash Flow from Financing Activities</b>		
	Interest Paid	(163.84)	(83.24)
	(Increase)/Decrease in Financial and Other - Non Current Assets	(41.43)	(59.07)
	Increase/(Decrease) in Short Term Borrowings	414.06	86.07
	Increase/(Decrease) in Lease Liabilities	(13.35)	(10.57)
	Increase/(Decrease) in Long Term Borrowings	(364.94)	1,127.04
	Dividend Paid	(148.09)	(296.18)
	<b>Net Cash used in Financing Activities</b>	<b>(317.59)</b>	<b>764.05</b>
D.	Net Increase/(Decrease) in Cash and Bank Balance	(403.97)	(191.17)
	Cash & Bank Balance at beginning of the year	518.24	709.41
	<b>Cash &amp; Bank balances at the end of the year</b>	<b>114.26</b>	<b>518.24</b>

For & on behalf of the Board  
Chemcrux Enterprises Limited

Girish Kumar Shah  
Whole Time Director  
DIN : 00469291

Place : Vadodara  
Date : 20th May, 2025

**INDEPENDENT AUDITOR'S REPORT**

Independent Auditors Report on the Standalone Annual Financial Results of M/s Chemcrux Enterprises Limited for the quarter and year ended on 31<sup>st</sup> March, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

TO  
THE BOARD OF DIRECTORS  
CHEMCRUX ENTERPRISES LIMITED  
Vadodara

**Report on the Audit of the Standalone Financial Results****Opinion**

We have audited the accompanying Standalone Financial Results (the "Statement") of **Chemcrux Enterprises Limited** (the "Company") for the quarter and year ended March 31, 2025 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement :

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended on March 31, 2025

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial results.





### **Management's Responsibilities for the Standalone Financial Results**

These standalone financial results have been prepared on the basis of the standalone financial statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors' are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.



We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





### Other Matters

- a) During the fourth quarter of the current year, the Company acquired an additional 50% equity interest in Kalichem Private Limited, which was previously a joint venture with 50% ownership. As a result of this acquisition, Kalichem Private Limited has become a wholly-owned subsidiary of the Company effective from 27.02.2025. This transaction does not impact these standalone financial results except for disclosure of the investment in the subsidiary.
- b) The Standalone Financial Results include the results for the quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subjected to a limited review by us as required under the Listing Regulations.

Our Opinion is not modified in respect of the above Other Matters

For Naresh & Co  
Chartered Accountants  
FRN: 106928W

CA Harin Parikh  
Partner

M.No. 107606

UDIN: 25107606BMOJDU3725

Place: Vadodara

Date: 20<sup>th</sup> May, 2025



Regd. Office :-  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



20<sup>th</sup> May 2025

To  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400 001

Dear Sir/Madam,

**Subject:** Declaration in respect of unmodified opinion on Audited Standalone Financial Statements & Results for the Financial Year ended 31<sup>st</sup> March 2025.

**Ref.:** BSE Scrip ID: **CHEMCRUX** BSE Scrip Code: **540395**

In terms of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; I, Girishkumar Shah, Whole-time Director of **Chemcrux Enterprises Limited**, hereby declare that the Statutory Auditors of the Company viz. M/s Naresh & Co., Chartered Accountants (FRN 106928W); have issued Audit Report dated 20<sup>th</sup> May 2025 with unmodified opinion on the Annual Audited Standalone Financial Statements & Results for the financial year ended 31<sup>st</sup> March 2025.

Kindly take the above on your records.

**For CHEMCRUX ENTERPRISES LIMITED**

**Girishkumar Shah**  
**Whole-time Director**

## CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

## AUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2025

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	Quarter Ended			Year ended	
		31-03-2025 Audited	31-12-2024 Unaudited	31-03-2024 Audited	31-03-2025 Audited	31-03-2024 Audited
I.	Revenue from operations	1,572.40	1,942.12	1,853.68	7,000.99	7,846.53
II.	Other income	23.52	60.55	34.70	148.74	133.55
III.	<b>Total Income ( I+II )</b>	<b>1,595.92</b>	<b>2,002.67</b>	<b>1,888.39</b>	<b>7,149.73</b>	<b>7,980.07</b>
IV.	<b>Expenses:</b>					
	Cost of materials consumed	669.64	869.45	794.14	2,978.53	2,533.25
	Purchase of Traded Goods	-	-	-	-	-
	Changes in inventories of finished goods, by-products and work in progress	(187.64)	(60.10)	(153.44)	(236.26)	579.79
	Employee benefits expense	222.35	217.48	201.37	856.44	882.91
	Finance costs	69.00	59.60	13.00	174.55	83.24
	Depreciation and amortization expense	98.96	92.09	55.04	320.56	228.52
	Other expenses	656.84	646.08	748.88	2,479.38	2,529.21
V.	<b>Total expenses (IV)</b>	<b>1,529.15</b>	<b>1,824.61</b>	<b>1,659.00</b>	<b>6,573.19</b>	<b>6,836.92</b>
VI.	<b>Profit Before Share in profit of Joint Venture (III-IV)</b>	<b>66.76</b>	<b>178.06</b>	<b>229.39</b>	<b>576.54</b>	<b>1,143.15</b>
VII.	<b>Share in Profit/(Loss) of Joint Venture (Net of Tax)</b>	-	(0.50)	-	(0.50)	-
VIII.	<b>Profit Before Tax</b>	<b>66.76</b>	<b>177.56</b>	<b>229.39</b>	<b>576.04</b>	<b>1,143.15</b>
IX.	<b>Tax expense :</b>					
	Current tax	2.66	26.98	50.19	74.94	285.00
	Deferred tax	43.41	19.59	(12.59)	110.85	11.89
	Income tax relating to earlier years	0.07	(1.17)	(29.45)	(1.11)	1.83
		<b>46.13</b>	<b>45.40</b>	<b>8.15</b>	<b>184.68</b>	<b>298.72</b>
X.	<b>Profit for the period</b>	<b>20.63</b>	<b>132.16</b>	<b>221.24</b>	<b>391.36</b>	<b>844.43</b>
XI.	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to profit or loss					
	- Defined Benefit Plan	18.88	3.47	(20.18)	26.18	(45.09)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.75	0.87	(5.08)	6.59	(11.35)
	(iii) Items that will be reclassified to profit or loss					
	-Fair Value Gain on Investments	39.91	11.85	39.19	126.92	133.65
	(iv) Income tax relating to items that will be reclassified to profit or loss	10.04	2.98	9.86	31.95	33.64
	<b>Total other comprehensive income, net of tax</b>	<b>43.99</b>	<b>11.46</b>	<b>14.22</b>	<b>114.57</b>	<b>66.27</b>
XII.	<b>Total comprehensive income for the period</b>	<b>64.63</b>	<b>143.62</b>	<b>235.47</b>	<b>505.93</b>	<b>910.70</b>
XIII.	<b>Earnings per equity share (Nominal value per share Rs. 10/-)</b>					
	- Basic (Rs.)	0.14	0.89	1.49	2.64	5.70
	- Diluted (Rs.)	0.14	0.89	1.49	2.64	5.70






**Notes to Consolidated Financial Results :**

- 1 List of Entities Consolidated included in the  
**Kalichem Private Limited**  
Joint Venture till 26.02.2025  
Wholly-Owned Subsidiary from 27.02.2025
- 2 The above consolidated audited financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 3 The above consolidated audited financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 20th May, 2025
- 3 The above consolidated audited financial results have been audited by the Statutory Auditors as required under Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended.
- 4 During the last quarter of the year, M/s. Chemcrux Enterprises Ltd which held 50% stake in Kalichem Private Limited the Company, acquired the balance 50% stake from the co-venturer Company M/s. Kalintis Healthcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of M/s. Chemcrux Enterprises Ltd. (now the Holding Company) from that date.
- 4 The Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2024, the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business Combinations
- 5 M/s. Kalichem had commenced commercial production on 26th November 2024 and had incurred losses till 27th February, 2025 i.e. the date on which it became a wholly owned subsidiary. As an co-venturer holding 50% equity in the Joint Venture till that date, the Company was required to recognise its share of the losses. However, since the cost of total investment of the Company in the Joint Venture was less than the share of loss, it has recognized the loss the extent of ₹ 0.50 lakh only, i.e. to the extent of investment, in accordance with Ind AS 28 in the third quarter of the current year itself. Further, the acquisition of the balance stake at par value of Rs. 0.50 lacs would have resulted in a Goodwill but the same has been treated as impaired due to losses of Kalichem Private Limited. Upon conversion to a wholly owned subsidiary, the Company has consolidated the subsequent transactions as per Ind AS 110 and also recognised its total share of losses of Kalichem Private Limited in its own Reserves and Surplus.
- 6 The Standalone Financial Results of Kalichem Private Limited for the quarter and year ended on 31st March, 2025 and 31st March, 2024 have been audited by the respective statutory auditors who have who have furnished their Unmodified Opinion on the same in the respective Independent Audit Reports.
- 7 The figures of the quarter ended March 31, 2025 and quarter ended March 31 2025 are the balancing figures between audited figures in respect of the full financial and the year to date figures Upto the third quarter of the respective financial year which were subject to limited review by the respective Statutory Auditors as required under the Listing Regulations
- 8 The Holding Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of in AS 108, on Operating Segment, constitute a single operating segment.
- 9 The Board of Directors of the Holding Company at its Board Meeting held on 20th May 2025, recommended a dividend @ 10% (i.e. Rs.1/-per share of FV Rs. 10/- each) as Final Dividend for the year ended on 31st March 2025, subject to the approval of the same by the shareholders in the ensuing annual general meeting.
- 10 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board**  
**Chemcrux Enterprises Limited**

  
**Girish Kumar Shah**  
Whole Time Director  
DIN : 00469291

**Place : Vadodara**  
**Date : 20th May, 2025**



CHEMCRUX ENTERPRISES LIMITED			
CIN : L01110GJ1996PLC029329			
Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007			
CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2025			
(Figures in Rs Lacs)			
	Particulars	As at 31st March, 2025	As at 31st March, 2024
I.	<b>ASSETS</b>		
(1)	<b>Non - Current Assets</b>		
	(a) Property, Plant and Equipment	7,580.93	3,182.84
	(b) Capital Work In Progress	161.08	2,105.78
	(c) Investment Property	67.78	67.78
	(d) Right of Use Assets	44.23	56.57
	(e) Other Intangible Assets	12.84	1.54
	(f) Financial Assets		
	(i) Investments	4.70	5.17
	(ii) Loans	-	350.00
	(iii) Others	200.70	234.04
	(g) Other Non - Current Assets	-	-
(2)	<b>Current Assets</b>		
	(a) Inventories	1,001.66	841.06
	(b) Financial Assets	-	
	(i) Investments	1,978.15	1,977.41
	(ii) Trade Receivables	1,178.36	1,529.98
	(iii) Cash and Cash Equivalents	101.64	7.09
	(iv) Other Bank Balances	12.88	511.14
	(v) Loans	23.48	23.02
	(vi) Others	7.19	6.18
	(c) Other Current Assets	329.34	87.07
	<b>Total Assets</b>	<b>12,704.95</b>	<b>10,986.68</b>
II.	<b>EQUITY AND LIABILITIES</b>		
(1)	<b>Equity</b>		
	(a) Equity Share Capital	1,480.88	1,480.88
	(b) Other Equity	5,981.61	5,744.97
	<b>Liabilities</b>		
(2)	<b>Non - Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Long Term Borrowings	2,804.79	2,152.68
	(ii) Lease Liabilities	60.70	77.24
	(iii) Other Financial Liabilities	-	-
	(b) Provisions	5.57	17.56
	(c) Deferred Tax Liability (net)	367.25	217.86
(3)	<b>Current Liabilities</b>		
	(a) Financial liabilities		
	(i) Short Term Borrowings	1,348.00	401.96
	(ii) Lease Liabilities	16.54	13.35
	(iii) Trade Payables		
	a) Total Outstanding Dues of Micro Enterprises and Small Enterprises	45.02	264.41
	b) Total Outstanding Dues of Creditors Others than Micro Enterprises and Small Enterprises	403.53	333.61
	(iv) Other Financial Liabilities	72.55	159.69
	(c) Other Current Liabilities	118.50	106.96
	(b) Provisions	-	-
	(d) Current Tax Liabilities (Net)	-	15.52
	<b>Total Equity and Liabilities</b>	<b>12,704.95</b>	<b>10,986.68</b>


For & on behalf of the Board  
Chemcrux Enterprises Limited

Girish Kumar Shah  
Whole Time Director  
DIN : 00469291

Place : Vadodara  
Date : 20th May, 2025

CHEMCRUX ENTERPRISES LIMITED			
CIN : L01110GJ1996PLC029329			
Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007			
STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2025			
(Figures in Rs Lacs)			
Sr.	Particulars	Year ended 31st March , 2025	Year ended 31st March , 2024
A.	<b>Cash flow from Operating Activities :</b>		
	Net Profit before Tax & Extra Ordinary Items	576.54	1,143.15
	Adjustment for :	-	-
	Depreciation & Write-offs	320.56	228.52
	Loss/(Profit) on Sale of PPE	(5.98)	16.84
	Interest Expense	174.55	83.24
	Interest Income	(74.67)	(39.17)
	Gain on Mutual Funds	(23.81)	(34.38)
	Gratuity Expense	14.20	7.22
	<b>Operating Profit before Working Capital Changes</b>	<b>981.39</b>	<b>1,405.43</b>
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	351.92	(186.06)
	(Increase)/Decrease in Inventories	(79.10)	568.01
	(Increase)/Decrease in Loans & Advances	(1.21)	(12.55)
	(Increase)/Decrease in other current assets	17.78	280.76
	Increase/(Decrease) in Trade Payable	(268.15)	(205.21)
	Increase/(Decrease) in Other Non Current Liabilities	(0.02)	-
	Increase/(Decrease) in Other Current Liabilities	(101.51)	35.43
	Increase/(Decrease) in Long term provisions	-	17.56
	<b>Cash Generated from Operating Activities</b>	<b>901.12</b>	<b>1,903.36</b>
	Direct Taxes Paid	(141.82)	(269.48)
	<b>Cash Flow before Extra Ordinary Items</b>	<b>759.30</b>	<b>1,633.88</b>
	Prior Period Items ( being cash items )	-	-
	<b>Net Cash Flow from Operating Activities</b>	<b>759.30</b>	<b>1,633.88</b>
B.	<b>Cash Flow from Investing Activities</b>		
	Purchase of PPE	(839.60)	(2,428.51)
	Net Proceeds from Sale of PPE	17.00	110.00
	Dividend Received	-	-
	Investments (Net)	149.48	(239.76)
	Loan Given to Related Parties	350.00	(70.00)
	Interest Received	74.67	39.17
	<b>Net Cash used in Investment Activities</b>	<b>(248.46)</b>	<b>(2,589.10)</b>
C.	<b>Cash Flow from Financing Activities</b>		
	Interest Paid	(174.55)	(83.24)
	(Increase)/Decrease in Financial and Other - Non Current Assets	(41.43)	(59.07)
	Increase/(Decrease) in Short Term Borrowings	399.12	86.07
	Increase/(Decrease) in Lease Liabilities	(13.35)	(10.57)
	Increase/(Decrease) in Long Term Borrowings	(937.22)	1,127.04
	Dividend Paid	(148.09)	(296.18)
	<b>Net Cash used in Financing Activities</b>	<b>(915.52)</b>	<b>764.05</b>
D.	Net Increase/(Decrease) in Cash and Bank Balance	(404.68)	(191.17)
	Cash & Bank Balance at beginning of the year	518.24	709.41
	Cash & Bank Balance of Subsidiary on date of acquisition	0.97	-
	<b>Cash &amp; Bank balances at the end of the year</b>	<b>114.52</b>	<b>518.24</b>

For & on behalf of the Board  
Chemcrux Enterprises Limited

  
Girish Kumar Shah  
Whole Time Director  
DIN : 00469291

Place : Vadodara  
Date : 20th May, 2025

**INDEPENDENT AUDITOR'S REPORT ON THE CONSOLIDATED FINANCIAL RESULTS OF CHEMCRIX ENTERPRISES LIMITED FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH, 2025 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**To the Board of Directors of Chemcruz Enterprises Limited**

**Opinion**

We have audited the accompanying Consolidated Annual Financial Results ("the Statement") of Chemcruz Enterprises Limited ("the Holding Company") and its Subsidiary (Holding Company and its Subsidiary together referred to as "the Group") for the quarter and the year ended 31<sup>st</sup> March 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('LODR Regulations')

In our opinion, and to the best of our information, and according to the explanations given to us and based on the consideration of our report on separate audited financial statements of subsidiary, the Statement :

(i) includes the annual financial results of the following entities :

Name of Subsidiary : Kalichem Private Limited

(ii) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations as amended; and

(iii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for quarter and the year ended 31<sup>st</sup> March 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.





### Management's Responsibilities for the Consolidated Financial Results

These Consolidated Financial Results have been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the Companies included in the Group responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the Companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.





As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Holding Company and / or its Subsidiary to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Holding Company and / or its Subsidiary to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the Holding Company and its Subsidiary to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

### Other Matters

- a) The Holding Company initially held 50% stake in Kalichem Private Limited making it a Joint Venture. The Holding Company acquired balance 50% stake in Kalichem Private Limited from the co-venturer M/s. Kalintis Healthcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of the Holding Company from that date.
- b) The Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2024, the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business Combinations
- c) M/s. Kalichem had commenced commercial production on 26th November 2024 and had incurred losses till 27th February, 2025 i.e. the date on which it became a wholly owned subsidiary. As a co-venturer holding 50% equity in the Joint Venture till that date, the Company was required to recognise its share of the losses. However, since the cost of total investment of the Company in the Joint Venture was less than the share of loss, it has recognized the loss the extent of ₹ 0.50 lakh only, i.e. to the extent of investment, in accordance with Ind AS 28 in the third quarter of the current year itself. Further, the acquisition of the balance stake at par value of Rs. 0.50 lacs would have resulted in a Goodwill but the same has been treated as impaired due to losses of Kalichem Private Limited. Upon conversion to a wholly owned subsidiary, the Company has consolidated the subsequent transactions as per Ind AS 110 and also recognised its total share of losses of Kalichem Private Limited in its own Reserves and Surplus.





- d) The Statement includes the figures relating to quarter and year ended 31<sup>st</sup> March, 2024 for which the financial results of M/s. Kalichem Private Limited were audited by other auditors and at which time M/s. Kalichem Private Limited was a Joint Venture and Consolidated under the Equity Method.
- e) The Consolidated Financial Results include the results for the quarter ended 31<sup>st</sup> March 2025 and quarter ended 31<sup>st</sup> March, 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year which were subject to limited review by us.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters.

For Naresh & Co  
Chartered Accountants  
FRN: 106928W

  
CA Harin Parikh  
Partner

M.No. 107606  
UDIN: 25107606BMOJDW1032



Place: Vadodara  
Date: 20<sup>th</sup> May, 2025

Regd. Office :-  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



20<sup>th</sup> May 2025

To  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400 001

Dear Sir/Madam

**Subject:** Declaration in respect of unmodified opinion on Audited Consolidated Financial Statements & Results for the Financial Year ended 31<sup>st</sup> March 2025.

**Ref.:** BSE Scrip ID: **CHEMCRUX**

BSE Scrip Code: **540395**

In terms of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; I, Girishkumar Shah, Whole-time Director of **Chemcrux Enterprises Limited**, hereby declare that the Statutory Auditors of the Company viz. M/s Naresh & Co., Chartered Accountants (FRN 106928W); have issued Audit Report dated 20<sup>th</sup> May 2025 with unmodified opinion on the Annual Audited Consolidated Financial Statements & Results for the financial year ended 31<sup>st</sup> March 2025.

Kindly take the above on your records.

**For CHEMCRUX ENTERPRISES LIMITED**

  
  
**Girishkumar Shah**  
**Whole-time Director**



Regd. Office :-  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



### **FY25 RESULTS HIGHLIGHTS**

Commenting on the results, Executive Chairman, Mr. Girishkumar Shah stated:

“As reflected in the financials, during the financial year 2024-25, the Company’s topline declined by 10% compared to FY 2023-24 and by 35% compared to FY 2022-23. However, we are pleased to report that sales volume performance was encouraging. In terms of quantity, sales were only 4% lower than FY 2023-24, and in fact, 21% higher than FY 2022-23. This demonstrates that the Company has been successful in sustaining its volumes and market demand. The decline in revenue is primarily attributable to pricing pressures, which have adversely impacted both topline and bottom-line performance.”

Year on Year Basis Comparison of Performances		
Particulars	YoY Change 2023-24 vs. 2024-25	YoY Change 2022-23 vs. 2024-25
Revenue from Operations	-10%	-26%
Operating Expenses	-7%	-18%
Gross Profit	-21%	-47%
PBT	-49%	-70%
PAT	-50%	-71%
Sales Quantity	-4%	+21%



#### **Factory**

4712-14, GIDC, Road South - 10, Ankleshwar - 393002 (Gujarat) India.  
Ph.: +91 2646 221427, 239737 | Email : sanjay@chemcrux.com